文献速递临床试验与 GCP基础与转化研究

动态对比增强MRI预测非小细胞肺癌骨转移患者对长春瑞滨-顺铂单用或联合重组人血管内皮抑制素治疗的反应:一项随机双盲安慰剂对照试验

Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet · 2016-01-01

这项在上海第六人民医院开展的4期随机双盲安慰剂对照试验,纳入33例初治非小细胞肺癌骨转移患者(可评估28例),比较长春瑞滨-顺铂联合重组人血管内皮抑制素与联合安慰剂的疗效。联合重组人血管内皮抑制素组客观缓解率更高(30% vs 0%,p<0.00001),中位总生存更长(21.44 vs 7.71个月,p=0.008),Ktrans下降幅度更大(60.0% vs 4.4%,p=0.026)。作者认为动态对比增强MRI定量分析可用于评估抗血管生成治疗后的骨转移疗效并预测生存。

要点

  • 联合重组人血管内皮抑制素组客观缓解率30% vs 对照组0%(p<0.00001)。
  • 联合组中位总生存21.44个月 vs 对照组7.71个月(p=0.008)。
  • Ktrans下降>50%者总生存长于下降≤50%者(13.2 vs 9.8个月,p=0.026)。

核心结论

  • 在长春瑞滨-顺铂基础上加用重组人血管内皮抑制素可提高非小细胞肺癌骨转移患者的治疗反应。
  • 动态对比增强MRI定量分析可用于评估抗血管生成治疗后骨转移的治疗反应并预测生存。

研究设计与样本

  • 4期随机、前瞻性、双盲、安慰剂对照临床试验,在上海市第六人民医院开展。
  • 纳入病理或细胞学确诊的非小细胞肺癌骨转移患者,年龄18至75岁,预期生存至少3个月。
  • 按2:1随机分为治疗组和对照组,由独立生物统计学家生成随机编码,双盲实施。
  • 治疗方案为长春瑞滨(25 mg/m2)联合顺铂(75 mg/m2)静脉给药,21天为一周期,第1天给药;重组人血管内皮抑制素(7.5 mg/m2)或安慰剂于周期第1-14天给药。
  • 可评估28例(治疗组20例,对照组8例);共入组33例(年龄52-70岁,男15例、女18例),5例被排除。

主要发现

  • 客观缓解率治疗组30% vs 对照组0%(p<0.00001)。
  • 疾病控制率治疗组80% vs 对照组75%(p=0.07)。
  • 中位总生存治疗组21.44个月(SD 17.28)vs 对照组7.71个月(SD 4.68),p=0.008。
  • Ktrans下降幅度治疗组60.0% vs 对照组4.4%(p=0.026)。
  • Ktrans下降大于50%者总生存13.2个月(SD 1.8)vs 下降至多50%者9.8个月(SD 0.2),p=0.026。

局限性

  • 作者指出本研究局限性包括患者数量少和单中心设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic bone disease is a frequent complication of advanced non-small-cell lung cancer and causes skeletal-related events which result in a poor prognosis. A standard method to assess the therapeutic response of bone metastases does not currently exist. We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated non-small cell lung cancer with bone metastases. METHODS: We did a phase 4, randomised, prospective, double-blind, placebo-controlled clinical trial in Shanghai Sixth People's Hospital, Shanghai, China. Inclusion criteria were non-small-cell lung cancer patients with bone metastases confirmed by pathology or cytology; available imaging data of pelvic metastatic lesions; aged 18 to 75 years old; expected survival at least 3 months; not receiving taxane, bevacizumab, thalidomide, rh-endostatin, or bisphosphonate; not having radiation therapy within 3 months of enrollment into study; normal results of routine blood tests, liver and kidney function, and electrocardiogram; absence of cardiovascular disease, autoimmune disease, vasculitis, severe infection, diabetes, and other concomitant disease; and signed informed consent. Exclusion criteria were receiving granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor during chemotherapy, intolerance to adverse reaction, and allergy to contrast agents. Patients were randomly assigned to treatment group and control group at a ratio of 2:1 by random code generation by an independent biostatistician in a double-blind fashion. Participants received either vinorelbine-cisplatin plus rh-endostatin or vinorelbine-cisplatin plus placebo. Vinorelbine (25 mg/m2) and cisplatin (75 mg/m2) were administered intravenously on the first day of a 21 day cycle. Patients received rh-endostatin (7·5 mg/m2) or placebo on days 1-14 of a cycle. The primary end points were objective response rate (complete remission+partial remission)/total × 100) and disease control rate (complete remission+partial remission+stable disease)/total × 100). Measurements including Ktrans, Kep, and Ve were evaluated by dynamic contrast-enhanced MRI before treatment and after completion of 2 treatment cycles. Blood concentrations of bone metabolites, tumour markers, and tumour vascular growth related factors were measured before and after treatment. Comparisons were made using paired t-test. Kaplan-Meier survival analysis was used to indicate the correlation between some measurements and progression-free survival or overall survival. The difference in Ktrans between patients who had partial remission or stable disease group and those who had disease progression was tested using the Chi-square test. All statistical analyses were performed with SPSS version 21.0. This trial was approved by the State Food and Drug Administration (No: S20050088) and China State Food and Drug Administration. The trial is registered with China Clinical Trials Registry, number chictr-ctr-09000569. Written informed consent and ethical approval was obtained. FINDINGS: We enrolled 33 patients (aged 52-70, 15 men and 18 women) of whom 28 were evaluable (20 in treatment group and 8 in control group). Five patients were excluded: 2 patients in treatment group and 1 patient in control group used granulocyte-macrophage colony stimulating factor, and 2 patients in the control group refused treatment. Objective response rate was higher (30% vs 0%; p<0·00001), mean overall survival was longer (21·44 [SD 17·28] vs 7·71 [4·68] months, p=0·008), and reduction in capillary permeability (measured by Ktrans) was greater (60·0% vs 4·4%; p=0·026) in the group given rh-endostatin than in the control group. Disease control rate was 80% in the treatment group and 75% in the control group (p=0·07). Overall survival was longer in patients with a greater than 50% reduction in Ktrans than in patients with a decrease of up to 50% (13·2 [1·8] vs 9·8 [0·2] months, p=0·026). INTERPRETATION: Addition of rh-endostatin to treatment with vinorelbine-cisplatin increased the treatment response in patients with non-small cell lung cancer and bone metastases. Quantitative analysis using dynamic contrast-enhanced MRI can be used to evaluate therapeutic response and to predict survival of bone metastases after anti-angiogenesis therapy. Limitations of this study include the small number of patients and the single-centre design. FUNDING: National Natural Science Foundation of China [grant number 81201628].

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Zhang R, Wang ZY, Li YH, et al. Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial. Lancet. 2016. PMID: 27968915. doi:10.1016/S0140-6736(16)32022-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。